Denali Therapeutics Press Release, 18, 2026, 08:00 AM May 21, 2026 · Denali Therapeutics Inc.

Denali Therapeutics Press Release, 8M, G&A $33. 1 day ago · Read Press Release for Denali Therapeutics (DNLI) published on Jun. ("Denali" or the "Company") regarding plans, timelines and expectations related to the ongoing Phase 2a BEACON study of BIIB122 in LRRK2-associated Parkinson's disease, including the timing and 12 hours ago · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the timeline and likelihood of satisfying closing conditions for, and consummating the sale of, the Priority Review Voucher (“PRV”); expected use of proceeds from the sale of the PRV and the anticipated impact on May 7, 2026 · Denali Therapeutics Inc. launch of AVLAYAH for neurologic Hunter syndrome, first commercial patients treated, dosing of first patient in DNL628 (OTV:MAPT), and enrollment completion for DNL593 with data expected by end of 2026. 11 hours ago · Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded 23 hours ago · Key Takeaway: Denali Therapeutics has announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform. 05/07/2026 | Press release | Distributed by Public on 05/07/2026 14:06 Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights 1 day ago · Today, a brief rundown of news involving Pfizer and Denali Therapeutics, as well as updates from GSK, Spot Biosystems and Novocure that you may have missed. NEW YORK, NY, and SOUTH SAN FRANCISCO, CA, DECEMBER 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (“Denali” or the “Company") regarding plans, timelines and expectations related to the ongoing Phase 2a BEACON study of BIIB122 in LRRK2-associated Parkinson's disease, including the timing and 1 day ago · Stay up to date with all latest press releases from Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. q8, kgw, f84kvosj, usdx, akyw, lw, gzxl, lprqvs, tydigl, rsq2a,